{
  "Clinical Information": [],
  "Patent Information": [],
  "Sequence Information": {
    "ID": "AP03685",
    "Peptide Name": "L-P  (V13K, Lys-rich; synthetic AMPs, UCLL1)",
    "Source": "Hybrid peptide, designed, man-made sequences",
    "Family": "Not found",
    "Gene": "Not found",
    "Sequence": "KWKSFLKTFKSAKKTVLHTALKAISS",
    "Sequence Length": 26,
    "UniProt Entry": "Ref",
    "Protein Existence": "Not found",
    "Biological Activity": [
      "Anti-Gram+",
      "Gram-",
      "Anti-MRSA"
    ],
    "Target Organism": "Not found",
    "Hemolytic Activity": "Not found",
    "Cytotoxicity": "Not found",
    "Binding Target": "Not found",
    "Linear/Cyclic": "Not found",
    "N-terminal Modification": "Not found",
    "C-terminal Modification": "Not found",
    "Nonterminal Modifications and Unusual Amino Acids": "Not found",
    "Stereochemistry": "Not found",
    "Structure": "Helix",
    "Structure Description": "Not found",
    "Helical Wheel Diagram": "Not found",
    "PDB ID": "",
    "Predicted Structure": "Not found",
    "Formula": "Not found",
    "Absent Amino Acids": "Not found",
    "Common Amino Acids": "Not found",
    "Mass": "Not found",
    "PI": "Not found",
    "Basic Residues": "Not found",
    "Acidic Residues": "Not found",
    "Hydrophobic Residues": "Not found",
    "Net charge": 8,
    "Boman Index": 1.05,
    "Hydrophobicity": "Not found",
    "Aliphatic Index": "Not found",
    "Half Life": "Not found",
    "Extinction Coefficient Cystines": "Not found",
    "Absorbance 280nm": "Not found",
    "Polar Residues": "Not found",
    "Function": "Not found",
    "Hydrophobic residue%": "42%",
    "Crucial residues": ""
  },
  "Literature Information": {
    "Literature": "Sequence analysis: APD analysis reveals this sequence is most similar (60.71%) toCP26An analog of a cecropin A (1–8) and melittin B (1–18) hybrid. K: 27%; S: 15%; L=A: 12%.  GRAVY: -0.21; M Wt: 2949.55; Mol formula:  C139H231N36O34; molar extinction coeff: 5550.Activity: active against Gram- E. coli ATCC 25922 or clinical strain (MIC 2-4 ug/ml), P. aeruginosa ATCC 27853 or clinical (MIC 8-16 ug/ml), K. pneumoniae ATCC 700603 or clinical (MIC 4-8 ug/ml), Gram+ S. aeurus ATCC 25923 or MRSA (MIC 64-128 ug/ml), S. epidermidis ATCC 12228 (MIC 4 ug/ml), B. subtilis ATCC 6633 (MIC 8 ug/ml), S. pneumoniae clinical isolate (MIC 8 ug/ml), alpha or beta Hemolytic streptococcus (MIC 64 ug/ml).Antimicrobial robustness:  NaCl-insensitive:E. coli (150 mM salt); CaCl2-sensitive:E. coli (2.5 mM salt); NaCl-sensitive:P. aeruginosa (150 mM salt); CaCl2-sensitive:P. aeruginosa (2.5 mM salt); NaCl-sensitive:S. epidermidis (150 mM salt); CaCl2-sensitive:S. epidermidis (2.5 mM salt); NaCl-insensitive:B. subtilis (150 mM salt); CaCl2-insensitive:B. subtilis (2.5 mM salt).Structure: helical in 50% TFE.Toxicity: HC50 500 ug/ml, not hemo.lytic.  Provided by Arjun Nair.",
    "Author": "Huang J, Hao D, Chen Y, Xu Y, Tan J, Huang Y, Li F, Chen Y. 2011",
    "Reference": "Peptides. 2011 Jul;32(7):1488-95. doi: 10.1016/j.peptides.2011.05.023.Pub-Med.",
    "Title": "Inhibitory effects and mechanisms of physiological conditions on the activity of enantiomeric forms of an alpha-helical antibacterial peptide against bacteria."
  },
  "3D Structure": []
}